<DOC>
	<DOC>NCT00736840</DOC>
	<brief_summary>This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.</brief_summary>
	<brief_title>BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis</brief_title>
	<detailed_description>Patients with chronic liver disease who have a recent biopsy will be offered a breath test. Correlation will be shown between histology and breath test in determining cirrhosis.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Age &gt;18 with chronic liver disease Patients that are taking hepatotoxin drug. Patient with severe congestive heart failure Patient with severe pulmonary hypertension Patient with uncontrolled diabetes mellitus Patient with previous surgical bypass surgery for morbid obesity Patient with extensive small bowel resection Patient currently receiving total parenteral nutrition Patient is a recipients of any organ transplant Patients that received any antiviral treatment within the past year Women who are pregnant Patient allergic to acetaminophen (such as Tylenol or any other related medications) Patient with history of chronic obstructive pulmonary disease or symptomatic bronchial asthma Patients unable to sign informed consent Patients that based on the opinion of the investigator should not be enrolled into this study Patients that are participating in other clinical trials evaluating experimental treatments or procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Methacetin</keyword>
	<keyword>Breath</keyword>
	<keyword>Test</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>